Covino has served as our Vice President, Finance and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control since March 2010, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002. He received his B.S. in Business Administration from Bryant University.
The company has return on total asset (ROA) of 18.08 % which means that it generated profit of $18.08 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 32.25 % meaning that it created $32.25 on every $100 dollars invested by stockholders.
The company currently holds 6.54 B in liabilities with Debt to Equity (D/E) ratio of 0.57 which is about average as compared to similar companies. Biogen Inc has Current Ratio of 2.9 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen Inc (BIIB) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 7,350 people. Biogen is listed under Pharmaceutical Products category by Fama And French industry classification.
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Inc to your portfolio